BOLDRINI, LAURA
BOLDRINI, LAURA
Universita' degli Studi di MILANO
Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study
2026 F. Ligorio, L. Provenzano, G. Fotia, M.V. Dieci, G. Curigliano, M. Giuliano, A. Botticelli, M. Lambertini, G. Rizzo, R. Pedersini, M. Sirico, N. La Verde, A. Gennari, A. Zambelli, A. Toss, M. Piras, M. Giordano, B. Tagliaferri, D. Generali, D. Sartori, G. Mazzoli, F. Jacobs, G. Armani, C. Sposetti, C. Zurlo, A. Menichetti, G. Griguolo, V. Faso, L. Boldrini, E. Munzone, A. Marra, E. Chiappe, S. Scagnoli, S. Pisegna, C. Capasso, C. De Angelis, G. Arpino, C. Criscitiello, V. Guarneri, G. Pruneri, L. Mariani, C. Vernieri
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
2026 C. Valenza, Y. Zheng, M. Milano, P.P.M. Berton Giachetti, D. Trapani, E. Giordano, L. Guidi, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, J.D. Etessami, N. Bianco, F. Conforti, G.J. Kirkner, C. Sangalli, K.E. Dibble, N. Fusco, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
2025 C. Valenza, E. Nicolò, M. Mongillo, D. Trapani, J. Katrini, L. Boldrini, L. Boscolo Bielo, G. Castellano, L. Guidi, G. Pellizzari, J. Villa, S. Derio, M. Lapresa, F. Gigli, G. Parma, E. Omodeo Salè, E. Derenzini, G. Curigliano, N. Colombo
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study
2025 C. Valenza, M. Mongillo, M.V. Visconti, J. Katrini, D. Trapani, L. Boldrini, L. Guidi, A. Farfalla, D. Malengo, G. Caruso, S. Derio, M. Lapresa, G. Parma, E. Biagioli, E. Omodeo Salé, G. Curigliano, N. Colombo
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2025 P.P.M. Berton Giachetti, S. Morganti, S. Gandini, F. Giudici, A. Marra, E. Nicolò, E. Zattarin, C. Corti, L. Boldrini, A. Verrazzo, C. Sposetti, M.G. Razeti, A. Carnevale Schianca, R. Scafetta, B. Taurelli Salimbeni, A. Esposito, P. Zagami, D. Trapani, B. Malagutti, R. Caputo, C. Vernieri, E. Munzone, S. Scagnoli, A. Botticelli, M. Lambertini, M. Giuliano, M. De Laurentiis, G. Viale, G. Bianchini, G. Curigliano, C. De Angelis, C. Criscitiello
Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms
2024 C. Valenza, M. Mongillo, F. Gigli, D. Trapani, J. Katrini, E. Nicolò, L. Boldrini, L. Boscolo Bielo, G. Castellano, L. Guidi, G. Pellizzari, S. Derio, M. Lapresa, G. Parma, E. Derenzini, G. Curigliano, N. Colombo
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow
2024 M. Cobanaj, C. Corti, E.C. Dee, L. Mccullum, L. Boldrini, I. Schlam, S.M. Tolaney, L.A. Celi, G. Curigliano, C. Criscitiello
Circulating tumor DNA in patients with locally advanced rectal cancer treated with multimodal treatment
2024 L. Gervaso, D. Ciardiello, G. Gregato, L. Guidi, C. Valenza, L. Ascione, L. Boldrini, S. Frassoni, C.A. Cella, F. Spada, L. Funicelli, G. De Roberto, W. Petz, S. Borin, M.A. Gerardi, L. Bottiglieri, D. Tamayo, E. Bertani, U. Fumagalli Romario, V. Bagnardi, G. Curigliano, F. Bertolini, N. Fazio, M.G. Zampino
Biomarkers for antibody-drug conjugates in solid tumors
2024 J. Katrini, L. Boldrini, C. Santoro, C. Valenza, D. Trapani, G. Curigliano
Antibody-drug conjugates in metastatic breast cancer: Sequencing, combinations and resistances
2024 L. Guidi, L. Boldrini, D. Trapani, G. Curigliano
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials
2024 E. Nicolò, S. Gandini, F. Giugliano, J. Uliano, O. D'Ecclesiis, S. Morganti, E. Ferraro, D. Trapani, P. Tarantino, P. Zagami, L. Boldrini, I. Caramella, A. Carnevale Schianca, M. Cristofanilli, M.A. Locatelli, A. Esposito, C. Belli, I. Minchella, C. Criscitiello, A. Marra, G. Curigliano
Real-world progression-free survival 2 with CDK4/6 inhibitors plus endocrine therapy and subsequent line: Results from the multicenter SISTER study
2023 S. Morganti, S. Gandini, E. Nicolo, E. Zattarin, C. Corti, A. Verrazzo, P.P.M.B. Giachetti, C. Sposetti, M.G. Razeti, B.T. Salimbeni, L. Boldrini, A.C. Schianca, R. Caputo, C. Vernieri, E. Munzone, M. Lambertini, M. De Laurentiis, G. Viale, G. Curigliano, C. Criscitiello
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials
2023 G. Castellano, C. Corti, L. Boldrini, L. Gervaso, C. Criscitiello, G. Curigliano
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023 E. Zattarin, D. Presti, L. Mariani, C. Sposetti, R. Leporati, A. Menichetti, C. Corti, C. Benvenuti, G. Fucà, R. Lobefaro, F. Ligorio, L. Provenzano, A. Vingiani, M. Del Vecchio, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, A. Esposito, C.A. Giorgi, L. Lalli, L. Boldrini, P.P.B. Giacchetti, A.C. Schianca, V. Guarneri, R. Pedersini, A. Losurdo, A. Zambelli, D. Generali, C. Criscitiello, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Fast Mimicking Diets and Other Innovative Nutritional Interventions to Treat Patients with Breast Cancer
2023 F. Giugliano, L. Boldrini, J. Uliano, E. Crimini, I. Minchella, G. Curigliano
Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives
2023 C. Valenza, G. Rizzo, M.I. Passalacqua, L. Boldrini, C. Corti, D. Trapani, G. Curigliano